Paul Frederick, MD
Ophthalmology · Huntsville, ALNPI 1366735623
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Alcon at 24.7% of the total.
Across 263 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$617
- Novartis$409
- Johnson & Johnson Surgical Vision, Inc.$326
- Bausch & Lomb Americas Inc.$304
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,93897%
- Other$1633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 45 | $1,509 |
| AbbVie(2 entities) | 64 | $1,022 |
| Sun Pharmaceutical Industries Inc. | 35 | $617 |
| Novartis | 25 | $409 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $326 |
| Bausch & Lomb Americas Inc. | 10 | $304 |
| Tarsus Pharmaceuticals, Inc. | 14 | $233 |
| Ocular Therapeutix, Inc. | 7 | $209 |
| Aerie Pharmaceuticals, Inc. | 6 | $201 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $185 |
| Oyster Point Pharma, Inc. | 9 | $180 |
| Eyevance Pharmaceuticals LLC | 9 | $178 |
| Baxter Healthcare | 1 | $163 |
| Amgen | 7 | $94 |
| Shire North American Group Inc | 5 | $86 |
| Rxsight Inc | 3 | $61 |
| Mallinckrodt Hospital Products Inc. | 2 | $56 |
| Harrow Eye, LLC | 3 | $56 |
| Dompe US, Inc. | 2 | $43 |
| Kala Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca | 2 | $36 |
| Glaukos Corporation | 2 | $31 |
| NEW World Medical,inc. | 2 | $26 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Carl Zeiss Meditec USA, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$269
- LOTEMAX SM$164
- MIEBO$142
- XIIDRA$142
- AcrySof IQ VIVITY IOL$137
- Centurion$136
- Tecnis Simplicity$135
- Rhopressa$125
- Rocklatan$125
- ARGOS$125
- DURYSTA$125
- DEXTENZA$122
- Tecnis IOL$116
How this compares
$6,101 in reported general payments places this provider in the 85th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 113 | $136,297 |
| XiidraLifitegrast | 48 | $58,803 |
| Cyclosporine | 71 | $44,511 |
| Prednisolone Acetate | 686 | $41,930 |
| RocklatanNetarsudil Mesylat/Latanoprost | 40 | $28,893 |
| MieboPerfluorohexyloctane/Pf | 29 | $21,015 |
| LumiganBimatoprost | 28 | $17,553 |
| MoxifloxacinMoxifloxacin Hcl | 618 | $17,440 |
| TyrvayaVarenicline Tartrate | 17 | $16,473 |
| Fluorometholone | 159 | $13,503 |
| RhopressaNetarsudil Mesylate | 29 | $12,137 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 53 | $8,871 |
| Restasis MultidoseCyclosporine | 13 | $8,178 |
| Loteprednol Etabonate | 52 | $7,407 |
| Brimonidine Tartrate | 72 | $6,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $1,022 | $165,705169 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $304 | $79,81777 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $201 | $41,03069 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $180 | $16,47317 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $185 | $7,40752 claims |
| AlconSimbrinza | $1,509 | $5,79926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Huntsville
- Caroline WatsonHuntsville$292K
- Jonathan RamseyHuntsville$8K
- William MitchellHuntsville$8K
- Robert FosterHuntsville$6K
- Patricia McCoyHuntsville$5K
- Robert StevensHuntsville$5K
- Walter HubickeyHuntsville$4K
- Bret FisherHomewood$545K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.